Schizophrenia

...ba href=/schizophrenia/a/b and has no access to money.

He does not have any family or friends in the Lower Mainland and cannot find his way back to his residence without assistance.

Raymond is Caucasian, 5’5”, with mostly dark hair that has some grey.

He was last seen wearing a beige or tan button-up sweater with a black diamond or checkered design.

Anyone with information about his whereabouts is asked to contact Surrey RCMP at 604-599-0502.

� Copyright 2007 Surrey Leader !

- ...

...ba href=/schizophrenia/a/b, a disorder characterized by hallucinations that affects 24 million people worldwide, according to the World Health Organization in Geneva.

The pills also are gaining wider use for adolescents with depression, autism and hyperactivity, dementia in the aged and even insomnia.

Almost half of Seroquel sales in 2006 were for disorders for which AstraZeneca has yet to gain regulatory approval, according to Datamonitor Plc, a London-based market research firm.

The other half was for approved indications such as treating ba href=/schizophrenia/a/b and for bi-polar disorder, also known as manic depression, according to Terence McManus, a Datamonitor analyst.

The amount of off-label use is ``across the class,'' McManus said in an interview March 6.

Seroquel sales increased 24 percent in 2006 to $3.4 billion.

Revenue may jump 30 percent more this year to $4.4 billion, according to David Seemungal, an analyst at Standard & Poor's Equity in London.

He estimates that Seroquel sales of London- based AstraZeneca will peak in 2010 at $5.75 billion.

`Policies in Place' ``We have policies in place that provide direction around the appropriate promotion of our product,'' said Jim Minnick, an AstraZeneca spokesman.

Lilly's spokeswoman Carole Puls said the drugmaker doesn't promote off-label use.

Johnson & Johnson spokesman Srikant Ramaswami declined to comment on why off-label use is increasing.

``We promote our products only for their...

...ba href=/schizophrenia/a/b, a disorder characterized by hallucinations that affects 24 million people worldwide, according to the World Health Organization in Geneva.

The pills also are gaining wider use for adolescents with depression, autism and hyperactivity, dementia in the aged and even insomnia.

Almost half of Seroquel sales in 2006 were for disorders for which AstraZeneca has yet to gain regulatory approval, according to Datamonitor Plc, a London-based market research firm.

The other half was for approved indications such as treating ba href=/schizophrenia/a/b and for bi-polar disorder, also known as manic depression, according to Terence McManus, a Datamonitor analyst.

The amount of off-label use is ``across the class,'' McManus said in an interview March 6.

Seroquel sales increased 24 percent in 2006 to $3.4 billion.

Revenue may jump 30 percent more this year to $4.4 billion, according to David Seemungal, an analyst at Standard & Poor's Equity in London.

He estimates that Seroquel sales of London- based AstraZeneca will peak in 2010 at $5.75 billion.

`Policies in Place' ``We have policies in place that provide direction around the appropriate promotion of our product,'' said Jim Minnick, an AstraZeneca spokesman.

Lilly's spokeswoman Carole Puls said the drugmaker doesn't promote off-label use.

Johnson & Johnson spokesman Srikant Ramaswami declined to comment on why off-label use is increasing.

``We promote our products only for their...